Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, …
Medical - Instruments & Supplies
IT, Piombino Dese [HQ]
Ratios
5 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross Margin | 25.72 | 29.33 | 31.45 | 32.51 | 30.05 | |
| Profit Margin | 7.31 | 11.86 | 15.92 | 14.52 | 13.70 | |
| Operating Margin | 11.60 | 15.57 | 15.18 | 15.51 | 17.53 | |
|
EPS Growth
|
- - | 86.67 | 89.29 | - - | 1.89 | |
| EPS EUR | 15.00 | 28.00 | 53.00 | 53.00 | 54.00 | |
| Return on Assets (ROA) | 4.44 | 8.11 | 9.47 | 8.61 | 7.02 | |
| Return on Equity (ROE) | 14.77 | 25.29 | 15.96 | 14.34 | 12.85 | |
| Return on Invested Capital (ROIC) | 6.87 | 12.50 | 9.56 | 9.58 | 9.43 | |
| Solvency | ||||||
| Equity Ratio | - - | - - | - - | - - | - - | |
| Debt/Assets | 42.58 | 37.50 | 17.22 | 13.16 | 18.62 | |
| Debt/Equity | 141.50 | 116.92 | 29.02 | 21.93 | 34.05 | |
| Debt/EBITDA | 267.70 | 156.73 | -90.38 | -4.77 | 125.12 | |
|
Debt/Capitalization
|
58.59 | 53.90 | 22.49 | 17.98 | 25.40 | |
| Long-Term Debt/Capitalization | 53.50 | 48.65 | 19.32 | 12.97 | 17.64 | |
| Interest Debt per Share EUR | 1.44 | 1.39 | 0.99 | 0.94 | 1.47 | |
| Debt Growth | 18.48 | -3.37 | -32.71 | -10.61 | 82.74 | |
| Liquidity | ||||||
| Current Ratio | 170.98 | 155.86 | 255.73 | 182.87 | 150.05 | |
| Quick Ratio | 120.55 | 111.64 | 211.63 | 135.38 | 103.21 | |
| Cash Ratio | 32.47 | 36.56 | 121.39 | 49.46 | 12.12 | |
| Operating Cash Flow Ratio | - - | - - | - - | - - | - - | |
| Turnover | ||||||
| Inventory Turnover | 302.18 | 335.69 | 388.52 | 311.25 | 279.95 | |
| Receivables Turnover | 281.35 | 338.04 | 303.10 | 266.24 | 203.31 | |
| Payables Turnover | 419.27 | 394.02 | 351.03 | 277.55 | 267.47 | |
|
Asset Turnover
|
60.82 | 68.39 | 59.49 | 59.28 | 51.28 | |
| Fixed Turnover | 174.81 | 195.27 | 203.15 | 148.89 | 101.48 | |
| Coverage | ||||||
| Interest Coverage | 1,109.88 | 1,720.20 | 681.48 | 512.00 | 4,410.13 | |
| Asset Coverage | 100 | 100 | 400 | 500 | 400 | |
| Cash Flow Coverage (CFGR) | 11.33 | 42.88 | 54.57 | 47.31 | 26.70 | |
| EBITDA Coverage | 1,900 | 2,600 | 900 | 700 | 6,200 | |
| Dividend Coverage | -600 | -800 | -1,100 | -1,000 | -1,000 | |
| Time Interest Earned (TIE) | 100 | 200 | 200 | 200 | 200 | |
| Market Prospects | ||||||
| Dividend Yield | 0.13 | 0.21 | 0.21 | 0.30 | 0.22 | |
| Earnings Yield | 0.84 | 1.84 | 2.57 | 3.22 | 2.23 | |
|
Price/Earnings (P/E)
|
11,843.47 | 5,425.94 | 3,890.56 | 3,109.74 | 4,491.80 | |
| Price/Earnings Growth (PEG) | - - | 62.61 | 43.57 | - - | 2,380.65 | |
|
Price/Book (P/B)
|
1,748.76 | 1,372.03 | 620.87 | 446.05 | 577.12 | |
| Price/Tangible Book (P/TB) | 1,748.76 | 1,372.03 | 620.87 | 446.05 | 577.12 | |
| Price/Sales (P/S) | 865.32 | 643.48 | 619.25 | 451.58 | 615.32 | |
|
Price/Cash Flow (P/CF)
|
10,905.67 | 2,736.85 | 3,920.36 | 4,300.32 | 6,347.63 | |
| Price/Free CF (P/FCF) | -14,817.00 | 7,141.54 | 25,973.35 | -3,176.95 | -1,983.36 | |
| Price/Operating CF (P/OCF) | 10,905.67 | 2,736.85 | 3,920.36 | 4,300.32 | 6,347.63 |